On March 24, GSK announced that the EMA had acceptedIts expanded use of Nucala (Mepolizumab) The application can be used asEosinophilic Phenotype of Chronic Obstructive Pulmonary Disease (COPD)Adjuvant Maintenance Therapy for Patients。The press release noted that if approved, mepolizumabExpected to become the first approved monthly biologic for COPD。
Screenshot source: GSK official websiteThis application is based on the positive results of the MATINEE study, a multicenter, randomized, double-blind, parallel-group, placebo-controlled study using 100mg subcutaneous injection of mepolizumab as an adjunctive treatment for subjects with COPD characterized by frequent exacerbations and eosinophil levels.The study enrolled patients with various COPD phenotypes and clinical manifestations. The primary endpoint of the study was the annual rate of moderate/severe acute exacerbations throughout the trial period.The study results showed that, compared with placebo, mepolizumab canSignificantly reduce the annualized rate of moderate/severe acute exacerbations with clinical significance. The specific research results will be announced at future scientific conferences.Mepolizumab is a monoclonal antibody targeting interleukin-5, which has been approved globally for various IL-5 mediated diseases, includingIncludeChronic Rhinosinusitis with Nasal Polyps, Eosinophilic Asthma, Allergic Granulomatosis Vasculitis, Hypereosinophilic Syndrome, Asthma。Currently, MepolizumabNot yet approved for the treatment of COPD in any country。IL-5 is a core cytokine in type 2 inflammation, which is a potential driving factor behind various diseases.The incidence of this type of inflammation in COPD patients is as high as 40%., has become a major trigger for symptom exacerbation and acute episodes, potentially leading to hospitalization and/or emergency department visits. COPD affects more than 390 million people globally.Cover Source: Corporate LogoDisclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment options. If needed, please consult and contact正规医疗机构. Editor：ccaiPR Article Coordination: WeChat insightxbSubmissionWeChat: insightxb; Email: insight@dxy.cn Diversified functions, traceable data……Insight Database Web Version Awaits Your Experience Click to read the original text,ImmediatelyUnlock！
